Navigation

Search the NICE 'do not do' recommendations database

You can search the NICE 'do not do' recommendations database by:

  • typing in a specific term in the 'do not do' recommendations box
  • selecting an appropriate topic
  • selecting the type of source guidance.

To see the full list of all NICE 'do not do' recommendations leave all the fields blank and click the 'Search' button.

Antenatal care

Results 1-10 of 24

Guidance ID NICE 'do not do' recommendation Interventions
CG62 Iron supplementation should not be offered routinely to all pregnant women. It does not benefit the mothers or the babys health and may have unpleasant maternal side effects. iron supplementation
CG62 Pregnant women should be informed that few complementary therapies have been established as being safe and effective during pregnancy. Women should not assume that such therapies are safe and they should be used as little as possible during pregnancy. complementary therapies
CG62 The effectiveness and safety of oral treatments for vaginal candidiasis in pregnancy are uncertain and these treatments should not be offered. oral antifungals
CG62 The routine anomaly scan (at 18 weeks 0 days to 20 weeks 6 days) should not be routinely used for Downâ??s syndrome screening using soft markers. The presence of an isolated soft marker, with an exception of increased nuchal fold, on the routine anomaly scan, should not be used to adjust the a priori risk for Downâ??s syndrome. The presence of an increased nuchal fold (6 mm or above) or two or more soft markers on the routine anomaly scan should prompt the offer of a referral to a fetal medicine specialist or an appropriate healthcare professional with a special interest in fetal medicine. anomaly scan
CG62 Pregnant women should not be offered routine screening for bacterial vaginosis because the evidence suggests that the identification and treatment of asymptomatic bacterial vaginosis does not lower the risk of preterm birth and other adverse reproductive outcomes. screening for bacterial vaginosis
CG62 Chlamydia screening should not be offered as part of routine antenatal care. chlamydia screening
CG62 The available evidence does not support routine cytomegalovirus screening in pregnant women and it should not be offered. cytomegalovirus screening
CG62 Pregnant women should not be offered routine screening for hepatitis C virus because there is insufficient evidence to support its clinical and cost effectiveness. screening for hepatitis C virus
CG62 Pregnant women should not be offered routine antenatal screening for group B streptococcus because evidence of its clinical and cost effectiveness remains uncertain. antenatal screening for group B streptococcus
CG62 Routine antenatal serological screening for toxoplasmosis should not be offered because the risks of screening may outweigh the potential benefits. antenatal serological screening for toxoplasmosis

Back to ´do not do´ recommendations home

This page was last updated: 28 March 2014

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.